The case for & against
Bull & Bear analysis
Biohaven Pharmaceuticals (NYSE: BHVN) is a leading biopharmaceutical company focused on developing innovative treatments for neurological conditions, particularly migraines. Its flagship product, NERTEC ODT, stands out as a dual-acting oral medication designed for both acute treatment and prevention of migraine headaches. Biohaven is currently navigating a promising pipeline that includes multiple neurovascular and neuropsychiatric disorders, signaling its commitment to addressing substantial unmet medical needs within the realm of neurology.
Bull says
- ↑Q4 revenue $463M, +627% YoY, driven by NERTEC ODT popularity.
- ↑Pfizer partnership provides $1.24B upfront plus milestones, boosting cash and global reach.
- ↑NERTEC ODT holds ~57% CGRP migraine market share post dual indication approval.
- ↑Late-stage pipeline targets multiple NDAs, diversifying future revenue streams.
- ↑Strong institutional interest and positive sentiment factors support stock momentum.
- ↑Favorable liquidity offsets weak profitability factors amid high R&D spending.
Bear says
- ↓Valuation premium poses risk if sales growth decelerates.
- ↓Q3 net loss $125M and Q4 R&D $76.4M signal high cash burn.
- ↓Competition from Amgen, Eli Lilly and Teva pressures CGRP market share.
- ↓Pipeline revenue hinges on regulatory approvals; delays could derail targets.
- ↓Payer access challenges and high deductibles may cap market penetration.
- ↓Weak profitability factors and elevated SG&A underscore financial headwinds.
Investment themes with BHVN
Genetic and drug innovations driving medical breakthroughs
Products and services targeting weight management
Earnings Call · Q4 2020 · Mgmt. Guidance
Transcript signals
Bull points
- Clinicians are starting to see certainly more patients and we're actually very bullish about that. The hope obviously accelerates. You know, that's what we're pushing to see. But we like the trend we're seeing currently and don't expect to really see anything go sideways in the coming weeks.
- when you look at last year's performance, which really was remarkable for any launch year, that was done in this very difficult environment. The team had demonstrated that we can launch and do well in the most difficult environments. BJ said we're seeing things finally start to open up with rates decreasing with COVID, and we think that's going to only increase our outlook.
- we're ecstatic with the success of NERTEC ODT to date and the significant impact we've had in the lives of so many patients with migraine and their loved ones.
Bear points
- as it relates to gross to net in the first quarter, so as we said, it's It really is just the nature of our business, and these are things like deductibles, patient deductibles, and prior authorizations. It's really a reset. When you start out the new year, deductibles start over, and prior auths have to be collected again, and that's really what's driving that impact this quarter.
- off-label use we think is pretty minimal at this point
- On EPS, we reported non-GAAP adjusted net loss for the three months ended December 31, 2020, of $161.7 million, or $2.69 per share loss. compared to $124.4 million or $2.38 per share loss for the same period in 2019.